XML 66 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Note 11 - Related Party Transactions (Details Textual)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Aug. 01, 2020
USD ($)
shares
Oct. 01, 2017
CAD ($)
Sep. 30, 2022
CAD ($)
Jan. 31, 2017
CAD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2020
USD ($)
Dec. 14, 2017
Dec. 02, 2017
Jul. 12, 2017
Notes Receivable, Related Parties, Current         $ 0   $ 0     $ 17,901      
Operating Lease, Liability, Total         $ 175,746   $ 175,746            
Lease Arrangement, 20 North Rear Road [Member]                          
Operating Lease, Monthly Rent       $ 4,000                  
Lessee, Operating Lease, Term of Contract (Year)       5 years                  
Stock Issued During Period, Shares, Issued for Settlement of Lease Termination (in shares) | shares 36,500                        
Stock Issued During Period, Value, Issued for Settlement of Lease Termination $ 50,700                        
Lessee, Operating Lease, Discount Rate 8.00%                        
Operating Lease, Right-of-Use Asset $ 48,110                        
Operating Lease, Liability, Total 45,118                        
Gain (Loss) on Termination of Lease (53,692)                        
Operating Lease, Expense           $ 8,690   $ 17,409          
Leases Office Space from R&D Labs Canada, Inc [Member]                          
Operating Lease, Monthly Rent   $ 2,608                      
Lessee, Operating Lease, Discount Rate         8.00%   8.00%            
Operating Lease, Liability, Total         $ 175,746   $ 175,746     164,997      
Operating Lease, Expense         $ 5,577 6,928 $ 10,749 13,253          
Operating Lease, Impairment Loss $ 146,795                        
Leases Office Space from R&D Labs Canada, Inc [Member] | Forecast [Member]                          
Operating Lease, Monthly Rent     $ 3,390                    
Long-term Convertible Notes Payable to Multiple Private Investors [Member]                          
Debt Instrument, Interest Rate, Stated Percentage                         5.00%
CEN Biotech Ukraine [Member] | XN Pharma [Member]                          
Ownership Percentage                     49.00%    
CEN Biotech Ukraine [Member]                          
Percentage of Related Party's Equity Interest Owned by Director                     25.50%    
Business Acquisition, Percentage of Voting Interests Acquired                     51.00%    
Emergence Global [Member]                          
Notes Receivable, Related Parties, Current                   17,901      
Joseph Byrne [Member]                          
Percentage of Related Party's Equity Interest Owned         5.00%   5.00%            
CEN Biotech Ukraine [Member]                          
Notes Receivable, Related Parties, Current                   17,901      
Due from Related Parties, Total         $ 1,299,328   $ 1,299,328     1,179,328      
Percentage of Related Party's Equity Interest Owned by Director                       51.00%  
CEN Biotech Ukraine [Member] | Equipment Sold to Related Party in Exchange for Note Receivable [Member]                          
Adjustments to Additional Paid in Capital, Dividends in Excess of Retained Earnings                 $ 255,141        
Notes Receivable, Related Parties                 44,859        
Board Members and Officers [Member] | Consulting Fees [Member]                          
Related Party Transaction, Amounts of Transaction         46,800 $ 31,200 78,000 $ 62,400          
Due to Related Parties, Total         $ 408,200   $ 408,200     $ 330,200      
R&D Labs Canada, Inc [Member] | Purchased Equipment in Exchange for Note Payable [Member]                          
Notes Payable, Related Parties                 $ 300,000